Readoutin 14d
Innovent Biologics (Suzhou) Co. Ltd. — Irinotecan OR Paclitaxel or Trifluridine/tipiracil( FTD/TPI)
Phase 3 primary completion: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001).
- Date
- Dec 2026
- Type
- Readout
- Indication
- Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma